Hedgehog Signaling Antagonist GDC-0449 (Vismodegib) Inhibits Pancreatic Cancer Stem Cell Characteristics: Molecular Mechanisms
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Recent evidence from in vitro and in vivo studies has demonstrated that aberrant reactivation of the Sonic Hedgehog (SHH) signaling pathway regulates genes that promote cellular proliferation in various human cancer stem cells (CSCs). Therefore, the chemotherapeutic agents that inhibit activation of Gli transcription factors have emerged as promising novel therapeutic drugs for pancreatic cancer. GDC-0449 (Vismodegib), orally administrable molecule belonging to the 2-arylpyridine class, inhibits SHH signaling pathway by blocking the activities of Smoothened. The objectives of this study were to examine the molecular mechanisms by which GDC-0449 regulates human pancreatic CSC characteristics in vitro. METHODOLOGY/PRINCIPAL FINDINGS: GDC-0499 inhibited cell viability and induced apoptosis in three pancreatic cancer cell lines and pancreatic CSCs. This inhibitor also suppressed cell viability, Gli-DNA binding and transcriptional activities, and induced apoptosis through caspase-3 activation and PARP cleavage in pancreatic CSCs. GDC-0449-induced apoptosis in CSCs showed increased Fas expression and decreased expression of PDGFRα. Furthermore, Bcl-2 was down-regulated whereas TRAIL-R1/DR4 and TRAIL-R2/DR5 expression was increased following the treatment of CSCs with GDC-0449. Suppression of both Gli1 plus Gli2 by shRNA mimicked the changes in cell viability, spheroid formation, apoptosis and gene expression observed in GDC-0449-treated pancreatic CSCs. Thus, activated Gli genes repress DRs and Fas expressions, up-regulate the expressions of Bcl-2 and PDGFRα and facilitate cell survival. CONCLUSIONS/SIGNIFICANCE: These data suggest that GDC-0499 can be used for the management of pancreatic cancer by targeting pancreatic CSCs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Spencer, P. M., Cameron, J. L., & Lin, L. (2000) · Cited by 7,202
Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,894 · cited 1×
“The current standard-of-care therapy, gemcitabine, extends patient survival by only a few weeks [3].”
BackgroundCore Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969 · cited 1×
“Activation of the SHH signaling cascade consistently induces Gli family transcription factors (Gli1 and Gli2), hence both Gli genes mRNA [46], expressed in pancreatic cancer cell lines and CSCs, stating potential involvement of SHH signaling in human pancreatic carcinogenesis.”
BackgroundOlive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170 · cited 3×
“To identify new therapeutic targets, inhibition of SHH signaling has been attempted in multiple human cancers [11,41,45].”
BackgroundHedgehog signaling in animal development: paradigms and principles
Ingham, P. W., & McMahon, A. P. (2001) · Genes & Development · doi:10.1101/gad.938601 · Cited by 2,985 · cited 1×
“formation during embryogenesis; however, deregulation of this pathway is responsible for several human cancers [8,10,11].”
BackgroundInhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma
Von Hoff, D. D., LoRusso, P. M., Rudin, C. M., Reddy, J. C., Yauch, R. L., Tibes, R., Weiss, G. J., Borad, M. J., Hann, C. L., Brahmer, J. R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905360 · Cited by 1,109 · cited 2×
“To identify new therapeutic targets, inhibition of SHH signaling has been attempted in multiple human cancers [11,41,45].”
BackgroundClement, V., Sanchez, P., de Tribolet, N., Radovanovic, I., & Ruiz i Altaba, A. (2007) · Current Biology · doi:10.1016/j.cub.2006.11.033 · Cited by 1,050
A paracrine requirement for hedgehog signalling in cancer
Yauch, R. L., Gould, S. E., Scales, S. J., Tang, T., Tian, H., Ahn, C. P., Marshall, D., Fu, L., Januario, T., Kallop, D., et al. (2008) · Nature · doi:10.1038/nature07275 · Cited by 961 · cited 1×
“Recent evidence from in vitro and in vivo studies suggests that the Sonic Hedgehog (SHH) signaling pathway [4] is aberrantly reactivated and recognized as one of the mediators in the majority of PCs; therefore, SHH blockade has the potential to prevent disease progression and metastatic spread [5].”
BackgroundWiznerowicz, M., & Trono, D. (2003) · Journal of Virology · doi:10.1128/jvi.77.16.8957-8951.2003 · Cited by 701 · cited 1×
“Transfection of packaging cells and infection of pancreatic CSCs were carried out using standard protocols [50] with some modifications.”
MethodMechanisms of Hedgehog pathway activation in cancer and implications for therapy
Scales, S. J., & de Sauvage, F. J. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.03.007 · Cited by 650 · cited 3×
“There, Smoothened activates an intracellular cascade that results in activation and nuclear translocation of Gli family transcription factor Gli2 [8].”
BackgroundCilia and Developmental Signaling
Eggenschwiler, J. T., & Anderson, K. V. (2007) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.23.090506.123249 · Cited by 530 · cited 1×
“Smoothened is then localized into the primary cilium of the cell, an organelle playing a critical role in SHH signaling [7].”
BackgroundStecca, B., Mas, C., Clement, V., Zbinden, M., Correa, R., Piguet, V., Beermann, F., & Ruiz i Altaba, A. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700776104 · Cited by 530 · cited 1×
“Melanomas and carcinomas of the prostate have further shown a SHH-Gli signaling axis [23].”
BackgroundInhibition of prostate cancer proliferation by interference with SONIC HEDGEHOG-GLI1 signaling
Sanchez, P., Hernández, A. M., Stecca, B., Kahler, A. J., DeGueme, A. M., Barrett, A., Beyna, M., Datta, M. W., Datta, S., & Ruiz i Altaba, A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404956101 · Cited by 514 · cited 2×
“Natural and synthetic Smoothened antagonists such as cyclopamine [24] and IPI-926 [11], respectively have inhibited proliferation, survival and have anti-tumor functions, resulting in abrogation of SHH signaling.”
BackgroundThe Sonic Hedgehog-Gli pathway regulates dorsal brain growth and tumorigenesis
Dahmane, N., Sánchez, P., Gitton, Y., Palma, V., Sun, T., Beyna, M., Weiner, H., & Ruiz i Altaba, A. (2001) · Development · doi:10.1242/dev.128.24.5201 · Cited by 479
Varnat, F., Duquet, A., Malerba, M., Zbinden, M., Mas, C., Gervaz, P., & Ruiz i Altaba, A. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900039 · Cited by 463 · cited 1×
“It has recently been suggested that SHH signaling progresses during colon carcinogenesis [25,26] and in metastatic disease [27] whereas in normal colonic tissue, SHH signaling is involved in differentiation [28].”
BackgroundHedgehog beyond medulloblastoma and basal cell carcinoma
Teglund, S., & Toftgård, R. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.01.003 · Cited by 426 · cited 1×
“SHH signaling is initiated by the binding of short-acting polypeptide ligand namely Shh (Sonic Hedgehog, Indian Hedgehog or Desert Hedgehog) to its receptor, Patched which thereby, diminishes the inhibitory effects of Patched on Smoothened [6].”
BackgroundBasal cell carcinomas in mice overexpressing Gli2 in skin
Grachtchouk, M., Mo, R., Yu, S., Zhang, X., Sasaki, H., Hui, C.-C., & Dlugosz, A. A. (2000) · Nature Genetics · doi:10.1038/73417 · Cited by 397 · cited 1×
“Gli2 is also expressed in many basal cell carcinomas [31], suggesting that these genes might also be involved in the development of PC, which could be consistent with its partial action as mediator of SHH signals [32].”
BackgroundNolan-Stevaux, O., Lau, J., Truitt, M. L., Chu, G. C., Hebrok, M., Fernández-Zapico, M. E., & Hanahan, D. (2009) · Genes & Development · doi:10.1101/gad.1753809 · Cited by 383 · cited 2×
“Gli2 translocates into the nucleus and induces the transcription of SHH target genes, such as Gli1, a reliable marker of SHH signaling [8,9].”
BackgroundGLI transcription factors: Mediators of oncogenic Hedgehog signalling
Kasper, M., Regl, G., Frischauf, A.-M., & Aberger, F. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2005.08.039 · Cited by 369 · cited 1×
“SHH-driven cancers arise from a variety of mutations that affect different components, including the key transcriptional effector Gli proteins, leads to a variety of human malignancies including medulloblastoma, rhabdomyosarcoma, melanoma, basal cell carcinoma, and breast, lung, liver, stomach, prostate, and pancreati…”
BackgroundImplications of peritoneal cytology for staging of early pancreatic cancer
Warshaw, A. L. (1991) · The American Journal of Surgery · doi:10.1016/0002-9610(91)90356-i · Cited by 312 · cited 1×
“Surgical resection is the only potentially curative therapeutic option for PC; however, due to the lack of early symptoms, the vast majority of patients present with metastatic disease, rendering their malignancy inoperable [1,2].”
BackgroundShankar, S., Nall, D., Tang, S.-N., Meeker, D., Passarini, J., Sharma, J., & Srivastava, R. K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016530 · Cited by 304 · cited 2×
“CSCs may be responsible for tumor onset, self-renewal/maintenance, mutation accumulation, and metastasis due to their ability to express anti-apoptotic and drug resistant proteins, thus sustaining tumor growth [33,34].”
BackgroundMethodSelf-citationFeldmann, G., Fendrich, V., McGovern, K., Bedja, D., Bisht, S., Alvarez, H., Koorstra, J.-B. M., Habbe, N., Karikari, C., Mullendore, M., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0573 · Cited by 276 · cited 1×
“These data suggest that SHH pathway is intact in pancreatic cancer cell lines and CSCs, and supports the concept that the binding of the Shh ligand to the Patched receptor diminishes its inhibitory effects on Smoothened, allowing signal transduction that will result in activation and nuclear translocation of Gli famil…”
BackgroundHutchin, M. E., Kariapper, M. S. T., Grachtchouk, M., Wang, A., Wei, L., Cummings, D., Liu, J., Michael, L. E., Glick, A., & Dlugosz, A. A. (2005) · Genes & Development · doi:10.1101/gad.1258705 · Cited by 274 · cited 1×
“Gli2 is also expressed in many basal cell carcinomas [31], suggesting that these genes might also be involved in the development of PC, which could be consistent with its partial action as mediator of SHH signals [32].”
BackgroundGli proteins and Hedgehog signaling: development and cancer
Ruiz i Altaba, A. (1999) · Trends in Genetics · doi:10.1016/s0168-9525(99)01840-5 · Cited by 252 · cited 1×
“The Gli family plays critical roles in the mediation and interpretation of SHH signals [15].”
BackgroundRegl, G., Kasper, M., Schnidar, H., Eichberger, T., Neill, G. W., Philpott, M. P., Esterbauer, H., Hauser-Kronberger, C., Frischauf, A.-M., & Aberger, F. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1085 · Cited by 248 · cited 1×
“We also determined the contributions of apoptotic cell death pathways (mitochondria-mediated intrinsic and death receptor signalingmediated extrinsic), based on the known regulation of PDGFRa upstream of Fas [2,48], and of Bcl-2, which may be a direct transcriptional target of both Gli1 and Gli2, a key anti-apoptotic…”
BackgroundTang, S., Fu, J., Nall, D., Rodova, M., Shankar, S., & Srivastava, R. K. (2012) · International Journal of Cancer · doi:10.1002/ijc.26323 · Cited by 203 · cited 4×
“Recent evidence from in vitro and in vivo studies suggests that the Sonic Hedgehog (SHH) signaling pathway [4] is aberrantly reactivated and recognized as one of the mediators in the majority of PCs; therefore, SHH blockade has the potential to prevent disease progression and metastatic spread [5].”
BackgroundInfluentialSelf-citationMultipotent CD15+ Cancer Stem Cells in Patched-1 –Deficient Mouse Medulloblastoma
Ward, R. J., Lee, L., Graham, K., Satkunendran, T., Yoshikawa, K., Ling, E., Harper, L., Austin, R., Nieuwenhuis, E., Clarke, I. D., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0342 · Cited by 182 · cited 1×
“SHH signaling events have been implicated in tumor cell proliferation and survival as well as is the molecular hallmark of different human tumor entities that include esophageal squamous cell carcinoma, basal cell carcinoma [38], subsets of medulloblastoma [39], prostate cancer [40], colon cancer [41], brain tumors [4…”
BackgroundHedgehog Signaling Drives Cellular Survival in Human Colon Carcinoma Cells
Mazumdar, T., DeVecchio, J., Shi, T., Jones, J., Agyeman, A., & Houghton, J. A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2315 · Cited by 159 · cited 7×
“Pharmacologic agents including cyclopamine (11), GDC-0499 and GANT-61 [41] have inhibited survival and antitumor functions in preclinical models of human cancers.”
BackgroundResultInfluentialEcke, I., Petry, F., Rosenberger, A., Tauber, S., Mönkemeyer, S., Heß, I., Dullin, C., Kimmina, S., Pirngruber, J., Johnsen, S. A., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-0946 · Cited by 138 · cited 1×
“SHH signaling events have been implicated in tumor cell proliferation and survival as well as is the molecular hallmark of different human tumor entities that include esophageal squamous cell carcinoma, basal cell carcinoma [38], subsets of medulloblastoma [39], prostate cancer [40], colon cancer [41], brain tumors [4…”
BackgroundSrivastava, R. K., Tang, S., Zhu, W., Meeker, D., & Shankar, S. (2011) · Frontiers in Bioscience-Elite · doi:10.2741/e266 · Cited by 132 · cited 1×
“CSCs may be responsible for tumor onset, self-renewal/maintenance, mutation accumulation, and metastasis due to their ability to express anti-apoptotic and drug resistant proteins, thus sustaining tumor growth [33,34].”
BackgroundSelf-citationHedgehog--Gli signaling in brain tumors: stem cells and paradevelopmental programs in cancer.
Altaba, A. R., Stecca, B., & Sánchez, P. (2004) · Cancer Letters · doi:10.1016/s0304-3835(03)00451-8 · Cited by 122 · cited 1×
“SHH signaling events have been implicated in tumor cell proliferation and survival as well as is the molecular hallmark of different human tumor entities that include esophageal squamous cell carcinoma, basal cell carcinoma [38], subsets of medulloblastoma [39], prostate cancer [40], colon cancer [41], brain tumors [4…”
BackgroundHashimoto‐Torii, K., Motoyama, J., Hui, C., Kuroiwa, A., Nakafuku, M., & Shimamura, K. (2003) · Mechanisms of Development · doi:10.1016/j.mod.2003.09.001 · Cited by 121
Regulation of Hedgehog signaling: a complex story.
Ogden, S. K., Ascano, M., Stegman, M. A., & Robbins, D. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.01.002 · Cited by 119 · cited 1×
“Recent evidence from in vitro and in vivo studies suggests that the Sonic Hedgehog (SHH) signaling pathway [4] is aberrantly reactivated and recognized as one of the mediators in the majority of PCs; therefore, SHH blockade has the potential to prevent disease progression and metastatic spread [5].”
BackgroundThe Hedgehog Pathway and Pancreatic Cancer
Hidalgo, M., & Maitra, A. (2009) · New England Journal of Medicine · doi:10.1056/nejmcibr0905857 · Cited by 110 · cited 3×
“These data suggest that SHH pathway is intact in pancreatic cancer cell lines and CSCs, and supports the concept that the binding of the Shh ligand to the Patched receptor diminishes its inhibitory effects on Smoothened, allowing signal transduction that will result in activation and nuclear translocation of Gli famil…”
BackgroundResultSonic hedgehog-Gli1 pathway in colorectal adenocarcinomas
Bian, Y. H., Huang, S.-H., Yang, L., Ma, X.-L., Xie, J.-W., & Zhang, H.-W. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i11.1659 · Cited by 84 · cited 1×
“SHH-driven cancers arise from a variety of mutations that affect different components, including the key transcriptional effector Gli proteins, leads to a variety of human malignancies including medulloblastoma, rhabdomyosarcoma, melanoma, basal cell carcinoma, and breast, lung, liver, stomach, prostate, and pancreati…”
BackgroundKatoh (2009) · International Journal of Oncology · doi:10.3892/ijo_00000328 · Cited by 81 · cited 2×
“It has recently been suggested that SHH signaling progresses during colon carcinogenesis [25,26] and in metastatic disease [27] whereas in normal colonic tissue, SHH signaling is involved in differentiation [28].”
BackgroundShi, T., Mazumdar, T., DeVecchio, J., Duan, Z.-H., Agyeman, A., Aziz, M. A., & Houghton, J. A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013054 · Cited by 80 · cited 1×
“Recently, genes have been profiled that are regulated downstream of Gli1 and Gli2 that are involved in cell proliferation and cell cycle [29,30], and cell survival (PDGFRa and Bcl-2) [22].”
BackgroundClement, V., Sanchez, P., de Tribolet, N., Radovanovic, I., & Altaba, A. R. I. (2007) · Current Biology · doi:10.1016/j.cub.2007.01.024 · Cited by 80
A Small‐Molecule Antagonist of the Hedgehog Signaling Pathway
Lee, J., Wu, X., di Magliano, M. P., Peters, E. C., Wang, Y., Hong, J., Hebrok, M., Ding, S., Cho, C. Y., & Schultz, P. G. (2007) · ChemBioChem · doi:10.1002/cbic.200700403 · Cited by 73
Gerber, A. N., Wilson, C. W., Li, Y.-J., & Chuang, P.-T. (2006) · Oncogene · doi:10.1038/sj.onc.1209891 · Cited by 58 · cited 1×
“SHH-driven cancers arise from a variety of mutations that affect different components, including the key transcriptional effector Gli proteins, leads to a variety of human malignancies including medulloblastoma, rhabdomyosarcoma, melanoma, basal cell carcinoma, and breast, lung, liver, stomach, prostate, and pancreati…”
BackgroundMarchese, R., Muleti, A., Pasqualetti, P., Bucci, B., Stigliano, A., Brunetti, E., Angelis, M. D., Mazzoni, G., Tocchi, A., & Brozzetti, S. (2006) · Pancreas · doi:10.1097/01.mpa.0000202938.63084.e3 · Cited by 53 · cited 13×
“In our study, GDC-0449 induced a marked increase in the expression of Fas and both DRs (TRAIL-R1/DR4 and TRAIL-R1/DR5), suggesting the potential involvement of these DRs in drug-induced apoptosis.”
BackgroundInfluentialHedgehog signaling pathway: Development of antagonists for cancer therapy
Xie, J. (2008) · Current Oncology Reports · doi:10.1007/s11912-008-0018-7 · Cited by 47 · cited 2×
“Constitutively, SHH-Gli signaling is active in basal cell carcinomas, medulloblastomas and cancers of esophagus, due to mutation in Patched or Smoothened [21,22].”
BackgroundClinical implications of hedgehog signaling pathway inhibitors
Liu, H., Gu, D., & Xie, J. (2011) · 癌症:英文版 · doi:10.5732/cjc.010.10540 · Cited by 35 · cited 1×
“Constitutively, SHH-Gli signaling is active in basal cell carcinomas, medulloblastomas and cancers of esophagus, due to mutation in Patched or Smoothened [21,22].”
BackgroundImmunoprevention of Basal Cell Carcinomas with Recombinant Hedgehog-interacting Protein
Vogt, A., Chuang, P., Hebert, J. L., Hwang, J., Lü, Y., Kopelovich, L., Athar, M., Bickers, D. R., & Epstein, E. H. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031190 · Cited by 34 · cited 1×
“SHH signaling events have been implicated in tumor cell proliferation and survival as well as is the molecular hallmark of different human tumor entities that include esophageal squamous cell carcinoma, basal cell carcinoma [38], subsets of medulloblastoma [39], prostate cancer [40], colon cancer [41], brain tumors [4…”
BackgroundCathepsin B is a target of Hedgehog signaling in pancreatic cancer
Hwang, J., Lee, S. H., Lee, K. H., Lee, K. Y., Kim, H., Ryu, J. K., Yoon, Y. B., & Kim, Y. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.08.028 · Cited by 32 · cited 1×
“Recently, genes have been profiled that are regulated downstream of Gli1 and Gli2 that are involved in cell proliferation and cell cycle [29,30], and cell survival (PDGFRa and Bcl-2) [22].”
BackgroundSelf-renewal mechanisms in neural cancer stem cells
Mantamadiotis, T., & Taraviras, S. (2010) · Frontiers in bioscience · doi:10.2741/3708 · Cited by 12 · cited 1×
“The SHH signaling pathway is a key regulator of physiological cell processes which include proliferation, differentiation, and apoptosis [35].”
Background
Cited by
EMT, CTCs and CSCs in tumor relapse and drug-resistance
Mitra, A., Mishra, L., & Li, S. (2015) · Oncotarget · doi:10.18632/oncotarget.4037 · Cited by 465
Rossi, R., Bellina, F., Lessi, M., & Manzini, C. (2014) · Advanced Synthesis & Catalysis · doi:10.1002/adsc.201300922 · Cited by 453
Cancer stem cells and chemoresistance: The smartest survives the raid
Zhao, J. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.02.008 · Cited by 437
The suture provides a niche for mesenchymal stem cells of craniofacial bones
Zhao, H., Feng, J., Ho, T.-V., Grimes, W., Urata, M., & Chai, Y. (2015) · Nature Cell Biology · doi:10.1038/ncb3139 · Cited by 429
Gastric cancer—molecular and clinical dimensions
Wadhwa, R., Song, S., Lee, J.-S., Yao, Y., Wei, Q., & Ajani, J. A. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.170 · Cited by 423
Metadata
- Authors
- Singh, B. N., Fu, J., Srivastava, R. K., & Shankar, S.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-11-08
- Volume
- 6
- Issue
- 11
- Pages
- e27306
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2124111260
- Cited by
- 197
- References
- 46
- FWCI
- 7.99
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.